GlassScriptPhysician profile
Caitlin Nass
NPI 1437273067
$45,994.31
in general payments reported to CMS, 2019-2025
18 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.27 · 2023: $774 · 2024: $28K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,462 · Food and Beverage: $6,854 · Consulting Fee: $3,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,942.00 |
| Travel and Lodging | $11,867.96 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,462.00 |
| Food and Beverage | $6,854.08 |
| Consulting Fee | $3,836.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28,054.02 | 2023-2025 | |
| Dexcom, INC. | $10,138.00 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Corcept Therapeutics | $5,593.87 | 2024-2025 | Korlym |
| Abbott Laboratories | $518.63 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Novo Nordisk INC | $490.81 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $361.54 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Insulet Corporation | $175.00 | 2025 | Omnipod |
| Medtronic, INC. | $163.49 | 2025 | Minimed 780g |
| Exact Sciences Corporation | $121.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Beta Bionics, INC. | $113.80 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $70.24 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lundbeck LLC | $43.91 | 2024 | Vyepti |
| Amgen INC. | $40.63 | 2024 | Evenity, Prolia, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.55 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $23.52 | 2024 | Heplisav-B |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.57 | 2025 | |
| Pfizer INC. | $19.71 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.36 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Nass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.